Celgene Regional Medical Liaison (MSL), Rheumatology / Dermatology - New England territory (MA, RI, NH, VT, ME) in Boston, Massachusetts
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
The Regional Medical Liaison (RML) is a member of a field-based team of scientists who function as an extension of the Medical Affairs organization. RMLs are responsible for developing and enhancing professional relationships with medical thought leaders involved in various phases of product development. RMLs provide medical information through scientific exchange in a fair-balanced manner and provide clinical/scientific support for Celgene and the Medical Affairs department at the direction of Medical Affairs management.
This is a field-based position and requires professionals with established credibility to interact with thought leaders and centers of excellence. The position involves travel of more than 50%.
*Candidates must live within the territory and be close to a major airport - Territory covers: Massachusetts, Rhode Island, New Hampshire, Vermont and Maine.
Responsibilities will also include, but are not limited to, the following:
Identify, develop and maintain collaborative relationships with current and future Key Opinion Leaders (KOLs) and healthcare stakeholders in disease states of strategic importance to Celgene.
Provide clinical presentations and information in response to unsolicited questions (as appropriate) in academic, community and healthcare provider setting in both group and one-on-one settings.
Collaborate with the Clinical organization to enhance patient enrolment in Celgene-sponsored clinical trials by identifying appropriate trial sites and interacting with investigators in ongoing studies.
Act as a primary liaison to investigators interested in developing and performing investigator initiated research.
Develop and execute territory plans in alignment with regional and national plans of action (POAs).
Assist in the reconnaissance of Market landscape determination and competitive intelligence including therapeutic trends and unmet needs within the appropriate disease states and marketplace and provide timely feedback/information on emerging clinical/scientific information and opportunities to internal stakeholders.
Provide scientific support at medical congresses
Completed Bachelor’s degree required.
Completed MD, DO, PharmD, MSN, PhD or MS in a scientific discipline highly desired.
Minimum of 5 years experience in Medical Affairs and/or drug development supporting specialty care compounds/products required.
3-5 years clinical or medical affairs experience in inflammation, immunology, rheumatology, or dermatology therapeutic area(s) required.
Clinical/protocol experience needed.
Overnight business travel of more than 50% is required.
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.